Skip to main content
Lbx Pharmacy Chain Joint Stock Company logo

Lbx Pharmacy Chain Joint Stock Company — Investor Relations & Filings

Ticker · 603883 ISIN · CNE1000023Q8 LEI · 300300C4YU1D5XYS0O68 Shanghai Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,772 across all filing types
Latest filing 2026-05-29 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603883

About Lbx Pharmacy Chain Joint Stock Company

http://www.lbxdrugs.com

Lbx Pharmacy Chain Joint Stock Company operates as a large-scale retail pharmacy enterprise. The company specializes in the distribution and retail sale of a wide range of pharmaceutical products, including prescription medications, over-the-counter drugs, and traditional Chinese medicines. Its product portfolio also encompasses medical equipment, nutritional supplements, and health-related consumer goods. The company utilizes a standardized management model across its extensive network of retail outlets to ensure service quality and product safety. In addition to physical retail operations, the company integrates digital health solutions and online-to-offline (O2O) services to enhance customer accessibility. Its business strategy focuses on providing comprehensive healthcare services and affordable pharmaceutical products to a broad consumer base.

Recent filings

Filing Released Lang Actions
关于控股股东股票质押的公告
Regulatory Filings Classification · 85% confidence The document is a mandatory disclosure by Laobaixing Pharmacy Co., Ltd. regarding its controlling shareholder’s share pledge. It details the number of shares pledged, pledgees, dates, and ratios. This is not a financial report itself, nor an earnings release or management discussion, but a regulatory announcement disclosing share pledge details. It does not fit categories like repurchase, dividend, or M&A, so it falls under general regulatory filings.
2026-05-29 Chinese
老百姓2025年年度股东会会议资料
AGM Information Classification · 93% confidence The document is titled “2025年年度股东会会议资料” and contains the agenda, meeting notices, and proposals for the company’s 2025 Annual General Meeting (to be held in June 2026). It includes meeting instructions, shareholder voting procedures, and detailed resolutions submitted for shareholder approval. This aligns exactly with “AGM Information” which covers materials shared at an Annual General Meeting, hence the correct classification is AGM-R.
2026-05-27 Chinese
关于召开2025年年度股东会的通知
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a notice of the 2025 Annual General Meeting of shareholders, detailing meeting date/time/location, agenda items, voting procedures, and including a proxy authorization form (“授权委托书”). It serves to solicit shareholder votes and provide information in advance of the meeting, fitting the Proxy Solicitation & Information Statement category.
2026-05-27 Chinese
2026年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '老百姓大药房连锁股份有限公司2026年第一季度报告' (Laobaixing Pharmacy Chain Co., Ltd. 2026 First Quarter Report). It contains detailed financial statements (Balance Sheet, Income Statement), management discussion on business operations, and key performance indicators for the first quarter of 2026. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report. Q1 2026
2026-04-22 Chinese
2025年度审计委员会履职报告
Governance Information Classification · 85% confidence The document is a detailed report by the company’s Audit Committee on its 2025 annual performance, covering committee composition, meetings held, deliberated items, oversight of external and internal audits, review of internal controls, and overall governance evaluation. It is not an external auditor’s standalone audit report, nor a general financial report or earnings release, but a governance‐focused committee report detailing internal rules, board committee structure, and governance practices. This aligns with the Governance Information category.
2026-04-22 Chinese
2025年度内部控制评价报告
Governance Information Classification · 75% confidence The document is a standalone 2025 Internal Control Evaluation Report (“内部控制评价报告”) issued by the company’s board and management, detailing internal control objectives, evaluation scope, defect standards, conclusions on control effectiveness, and remediation. This is not an annual financial report or an earnings announcement but rather a governance‐focused report on the company’s internal control systems. It best fits the “Governance Information (CGR)” category, which covers reports detailing internal rules, control practices, and governance processes.
2026-04-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.